title: Renal function at the time of renal biopsy as a predictor of prognosis in patients with primary AL-type amyloidosis.
abstract: BACKGROUND
  Amyloid light-chain (AL)-type amyloidosis is a plasma cell disorder with a poor prognosis for survival. Although prognostic factors, such as the number of organs involved and heart function or failure in respond to therapy have been clarified based on studies including a large series of patients, there are large interindividual differences in the prognosis of patients with primary AL-type renal amyloidosis.
  
  
  METHODS
  To clarify the prognostic factors of AL-type renal amyloidosis, we retrospectively investigated the clinical manifestations, histopathological data, and prognosis of 21 patients with amyloidosis, who had been diagnosed by renal biopsy.
  
  
  RESULTS
  Eleven patients died, at a mean observational time of 21.7 months after renal biopsy, whereas the mean observational time was 51.0 months for the 10 patients who survived. The creatinine clearance rate was significantly higher, and the serum creatinine concentration and the grade of interstitial damage were significantly lower in surviving patients (P < 0.05). The presence of amyloid fibrils in organs other than the kidney did not influence prognosis for survival. However, the intraventricular septum was thinner in surviving patients (P < 0.1). Thirteen patients had undergone melphalan-prednisolone therapy, but it did not affect prognosis for survival. Cox proportional hazard regression analysis revealed that the renal function at the time of diagnosis was a significant and independent prognostic factor for survival.
  
  
  CONCLUSIONS
  Our study demonstrated that renal function at the time of biopsy and renal interstitial damage are the best predictors of survival in AL-type renal amyloidosis.
authors.affiliation: Shinrakuen Hospital, 1-27 Nishi-Ariake, Niigata 950-2087, Japan. osw13nephrology@yahoo.co.jp.
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Osawa
authors.forename: Kazuko
authors.initials: K
authors.lastname: Kawamura
authors.forename: Daisuke
authors.initials: D
authors.lastname: Kondo
authors.forename: Naofumi
authors.initials: N
authors.lastname: Imai
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Ueno
authors.forename: Shinichi
authors.initials: S
authors.lastname: Nishi
authors.forename: Noriaki
authors.initials: N
authors.lastname: Iino
authors.forename: Masami
authors.initials: M
authors.lastname: Okada
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Suzuki
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hoshino
authors.forename: Hajime
authors.initials: H
authors.lastname: Yamazaki
authors.forename: Hidefumi
authors.initials: H
authors.lastname: Kishimoto
authors.forename: Hisaki
authors.initials: H
authors.lastname: Shimada
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Yamagishi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Ishiyama
authors.forename: Ichiei
authors.initials: I
authors.lastname: Narita
authors.forename: Fumitake
authors.initials: F
authors.lastname: Gejyo
mesh_terms: D000682:Amyloid; D000686:Amyloidosis / Q000401:mortality* / Q000473:pathology* / Q000503:physiopathology; D001706:Biopsy; D005260:Female; D006801:Humans; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D010950:Plasma Cells / Q000473:pathology; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies
chemical_list: D000682:Amyloid